Powering the Future of Biosimilar: A Collaborative Leap Towards Affordable and Effective Healthcare

In the dynamic landscape of healthcare, the development and availability of biosimilar have emerged as a promising solution to improve patient access to affordable and effective biological therapies. According to BioIntel360, global biosimilar market size is expected to record a CAGR of 26.2% during 2023-2027 to reach US$50,727.8 million by 2027, increasing from US$20,021.5 million in 2023. Over the last five years, the sector has recorded a CAGR of 28.0% to reach US$15,734.7 million in 2022.

Biosimilar, which are highly similar but not identical copies of existing biologic drugs, hold immense potential in reducing healthcare costs, expanding treatment options, and driving competition within the pharmaceutical industry. However, realizing these benefits requires a concerted effort and strong collaboration among various stakeholders, including regulatory bodies, healthcare providers, pharmaceutical manufacturers, and patient advocacy groups.

Collaboration plays a pivotal role in advancing the field of biosimilar by fostering innovation, ensuring patient safety, and overcoming the unique challenges associated with these complex therapeutic products. By engaging in an ongoing dialogue, these entities can streamline regulatory pathways, establish clear scientific standards, and promote confidence in the safety and efficacy of biosimilar.

Sandoz, a global leader in generic pharmaceuticals and biosimilar, has recently announced a significant partnership with Just – Evotec Biologics, a subsidiary of Evotec SE based in Seattle. This multi-year collaboration aims to enhance Sandoz's position as a standalone off-patent medicines company by focusing on the development and manufacturing of multiple biosimilar medicines. The agreement includes the option for expansion, marking a crucial step forward in Sandoz's strategy to strengthen its biosimilar portfolio and expand its global reach.
The partnership with Just – Evotec Biologics brings several advantages to Sandoz. It provides access to a highly efficient drug substance development platform and state-of-the-art manufacturing technology, which perfectly complements Sandoz's existing capabilities. This collaboration enables Sandoz to expand its current pipeline, which already includes more than 15 assets, to 24 assets. Additionally, it strengthens the business' dedication to maintaining the growth of its pipeline of early-stage biosimilar.
The strategic partnership is rooted in a shared vision between Sandoz and Just – Evotec Biologics. Both companies are dedicated to leveraging disruptive technologies that not only lower operational costs but also ensure the delivery of high-quality biosimilar at scale to patients worldwide. By harnessing the combined expertise and resources of both organizations, this collaboration aims to overcome manufacturing challenges and accelerate the development of biosimilar, providing patients with increased access to more affordable and effective treatment options.
Sandoz CEO Richard Saynor expressed his enthusiasm about the partnership, highlighting the shared commitment to leveraging disruptive technologies and the potential impact on global healthcare. He emphasized the importance of the collaboration in supporting the strategic expansion of Sandoz's pipeline, with new assets expected to be added in the future. This partnership also ensures a smooth transition for Sandoz's early biosimilar pipeline as the company finalizes its planned separation from Novartis, its parent company.
Over the next 12-18 months, the development of biosimilar under this partnership is expected to gain momentum. The combined expertise of Sandoz and Just – Evotec Biologics, along with the utilization of advanced manufacturing technologies, will facilitate the efficient and high-quality production of biosimilar medicines. This, in turn, will contribute to improving patient access to affordable therapies and addressing the unmet medical needs of diverse patient populations around the globe.

BioIntel360 suggests that as the biosimilar market continues to expand and gain traction, collaborations like this will play a crucial role in shaping the future of healthcare. The joint efforts of Sandoz and Just – Evotec Biologics represent a positive step forward in delivering affordable, high-quality biosimilar medicines to patients in need. With their shared vision, commitment, and complementary capabilities, this partnership is poised to make a significant impact in the field of biosimilar and ultimately benefit patients worldwide.